A Single-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-retroviral Activity of MK-8510 Monotherapy in Anti-retroviral-naïve HIV-1 Infected Participants
Latest Information Update: 02 Apr 2023
Price :
$35 *
At a glance
- Drugs MK 8510 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 23 Mar 2023 Status changed from not yet recruiting to withdrawn prior to enrolment due to business reasons.
- 03 Feb 2023 New trial record